87
Participants
Start Date
November 23, 2017
Primary Completion Date
June 25, 2020
Study Completion Date
June 25, 2020
Cobimetinib
Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
Atezolizumab
Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
Atezolizumab Cohort 7
Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
Orszagos Onkologiai Intezet, Budapest
Debreceni Egyetem Klinikai Kozpont, Debrecen
Jósa András Oktatókórház, Nyíregyháza
AZ Groeninge, Kortrijk
Memorial Sloan Kettering - Basking Ridge, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan-Kettering Cancer Center, Commack
Georgetown University Medical Center, Washington D.C.
Sarah Cannon Research Institute, Nashville
Kansas City - Menorah Medical Center, Kansas City
Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen, Heidelberg
Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Yonsei Cancer Center, Seoul
Barts & London School of Med; Medical Oncology, London
Royal Marsden Hospital - Fulham, London
The Royal Marsden, London
Hoffmann-La Roche
INDUSTRY